SCHEMBL23976646

SCHEMBL23976646

CN(CC(=O)NC1CCOCC1)c1nc(-c2cc(OCCOC3CCCCO3)ccn2)nc2c1CCC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
LMNA P02545 1/20 0.35
HDAC1 Q13547 3/20 0.33
HDAC8 Q9BY41 3/20 0.33
HDAC6 Q9UBN7 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HPGDS O60760 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
SLC2A1 P11166 3/20 0.32
SLC2A3 P11169 3/20 0.32
KDM4C Q9H3R0 1/20 0.32
ADORA3 P0DMS8 2/20 0.31
CNR1 P21554 3/20 0.31
CNR2 P34972 3/20 0.31
KDM4E B2RXH2 1/20 0.31
MITF O75030 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225268 1.00 MEN1 (0.35) MEN1KMT2ALMNAHDAC1HDAC8
SCHEMBL23975872 0.96 LMNA (0.39) MEN1KMT2ALMNAHDAC1HDAC8
SCHEMBL30225292 0.96 LMNA (0.39) MEN1KMT2ALMNAHDAC1HDAC8
SCHEMBL30118714 0.89 MEN1 (0.37) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL23975778 0.89 MEN1 (0.37) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL23976059 0.89 SYK (0.35) LMNAHDAC1HDAC8HDAC6HPGDS
SCHEMBL30225367 0.88 MEN1 (0.41) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL23976269 0.88 MEN1 (0.41) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL23976263 0.88 HPGDS (0.41) MEN1KMT2ALMNAHDAC1HDAC8
SCHEMBL30118665 0.88 HPGDS (0.41) MEN1KMT2ALMNAHDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 MEN1 2863/4885KMT2A 4375/4885LMNA 1425/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI MEN1 2553/4885KMT2A 4677/4885LMNA 1257/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI MEN1 2553/4885KMT2A 4677/4885LMNA 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.